A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2714-2719

  Morris, M J ^a,b   Eisenberger, M A ^c   Pili, R ^c   Denmeade, S R ^c   Rathkopf, D ^a,b   Slovin, S F ^a,b   Farrelly, J ^a   Chudow, J J ^a   Vincent, M ^d   Scher, H I ^a,b   Carducci, M A ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Astellas Pharma Inc   (United States)

Author keywords

Prostate cancer; Prostate stem cell antigen; Targeted therapy

Indexed keywords

DOCETAXEL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AGS PSCA; PACLITAXEL; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLADDER RUPTURE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DEHYDRATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; FATIGUE; HEART RATE; HUMAN; HYDRONEPHROSIS; HYPERGLYCEMIA; HYPOTENSION; IMMUNOGENICITY; INJECTION SITE PRURITUS; INJECTION SITE RASH; LEUKOPENIA; LIMB FRACTURE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; OPEN STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION;

EID: 84867126282     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds078     Document Type: Article

References (17)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
2. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
3. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
4. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
5. Saeki N, Gu J, Yoshida T, Wu X Prostate stem cell antigen: a Jekyll and Hyde molecule?. Clin Cancer Res 2010; 16: 3533-3538.
6. Reiter RE, Gu Z, Watabe T et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A 1998; 95: 1735-1740.
7. Gu Z, Thomas G, Yamashiro J et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19: 1288-1296.
8. Han KR, Seligson DB, Liu X et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004; 171: 1117-1121.
9. Lam JS, Yamashiro J, Shintaku IP et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005; 11: 2591-2596.
10. Saffran DC, Raitano AB, Hubert RS et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A 2001; 98: 2658-2663.
11. Wolpin BM. Poster Discussion Session: Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). In ASCO Annual Meeting. Chicago, IL 2011.
12. Wolpin BM, O'Reilly EM, Ko Y et al. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 2011; 29(Abstr 4031)
13. Jakobovits A, Gudas JM, Morrison K et al. Therapeutic potential of AGS-PSCA: a fully human monoclonal antibody to prostate stem cell antigen (PSCA) for the treatment of prostate cancer. In Prostate Cancer Symposium. 2005; Poster Session E. Abstract 203. Prostate Cancer Biology Orlando, FL
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
16. Amara N, Palapattu GS, Schrage M et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001; 61: 4660-4665.
17. Argani P, Rosty C, Reiter RE et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001; 61: 4320-4324.